Experience

We advised Oncopeptides on the private placement of shares

We advised the underwriters in connection with the SEC-registered offering

Davis Polk advised Xspray Pharma AB (publ) on a private placing of new shares. The private placing raised gross proceeds of approximately SEK 265 million.  Xspray was founded in 2003…

Davis Polk advised Smith & Nephew plc in connection with the establishment of a WKSI shelf and its debut SEC-registered shelf takedown of $1 billion aggregate principal amount of 2.032%…

Davis Polk advised NatWest Group plc in connection with its cash tender offer for any and all of certain series of its outstanding bank capital securities.NatWest Group is the holding…

Davis Polk advised Centogene N.V. on its $49 million follow-on public offering of 3,500,000 of its common shares, consisting of 2,000,000 common shares offered by Centogene and 1,500,000…

Davis Polk advised the representatives of the several underwriters in connection with an SEC-registered offering of $900 million aggregate principal amount of 4.700% notes due 2027, $1…

Davis Polk advised SEAS-NVE A.m.b.A. in connection with the unregistered sale of 9,532,013 shares of common stock in Ørsted A/S, representing 2.27% of Ørsted’s share capital, by way of an…

Davis Polk is advising Lazard & Co., Limited as joint financial adviser and sponsor and Numis Securities Limited as joint financial adviser and sole bookrunner to Bovis Homes Group PLC…

Davis Polk advised EQT AB (publ) on its initial public offering of shares and listing on Nasdaq Stockholm. The offering comprised 190,596,780 shares, of which existing EQT shareholders sold…